Clinical trials: Proliferative Diabetic Retinopathy
Rubeosis Iridis, Proliferative Diabetic Retinopathy
Use of Ranibizumab to Treat Rubeosis in Diabetics Prior to Cataract Surgery
The purpose of this study was to determine the safety of ranibizumab: a) as a surgical adjunct during cataract surgery in subjects with proliferative diabetic retinopathy (PDR) induced rubeosis and, b) in treatment of…
- Trial name
- NCT01069341
- Testing
- Ranibizumab
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Bhagat, Neelakshi, M.D., M.P.H.
Proliferative Diabetic Retinopathy
Intravitreal Aflibercept for Retinal Non-Perfusion in Proliferative Diabetic Retinopathy
The RECOVERY trial will assess the safety and tolerability of 2 mg intravitreal aflibercept injections (IAI) given monthly (Q4WK) or every 12 weeks (Q12WK) for the treatment of retinal capillary non-perfusion (RNP) associated…
- Trial name
- RECOVERY (NCT02863354)
- Testing
- Aflibercept
- Where
- 4 sites in United States
- Volunteers
- 43 people
- Sponsor
- Charles C Wykoff, PhD, MD
Nonproliferative Diabetic Retinopathy
The TIME-2b Study: A Study of AKB-9778 (Razuprotafib), a Novel Tie 2 Activator, in Patients With Non-Proliferative Diabetic Retinopathy (NPDR)
The purpose of this study is to evaluate the safety and efficacy of subcutaneously administered AKB-9778 15mg once daily or 15mg twice daily for 12 months in patients with moderate to severe non-proliferative diabetic retinopathy…
- Trial name
- TIME-2b (NCT03197870)
- Testing
- AKB-9778
- Where
- 53 sites in United States
- Volunteers
- 167 people
- Sponsor
- EyePoint Pharmaceuticals, Inc.
Diabetic Retinopathy
HORNBILL: A Study to Test Different Doses of BI 764524 in Patients Who Have Had Laser Treatment for a Type of Diabetic Eye Disease Called Diabetic Retinopathy With Diabetic Macular Ischemia
This is a study in people with a type of diabetic eye disease called diabetic retinopathy with diabetic macular ischemia. People who have had laser treatment for their diabetic retinopathy can participate in the study.
- Trial name
- HORNBILL (NCT04424290)
- Testing
- BI 764524
- Where
- 19 sites in United States, United Kingdom
- Volunteers
- 45 people
- Sponsor
- Boehringer Ingelheim
Non-Proliferative Diabetic Retinopathy, Cataract
Nepafenac Once Daily for Macular Edema - Study 2
The purpose of this study is to demonstrate superiority of Nepafenac Ophthalmic Suspension, 0.3% dosed once daily relative to Nepafenac Vehicle based upon clinical outcomes among diabetic participants following cataract surgery.
- Trial name
- NCT01872611
- Testing
- Nepafenac Ophthalmic Suspension, 0.3%, Vehicle, Prednisolone acetate
- Volunteers
- 819 people
- Sponsor
- Alcon Research
Proliferative Diabetic Retinopathy
Ranibizumab for Treatment of Persistent Diabetic Neovascularization Assessed by Wide-Field Imaging
Diabetic neovascularization refers to a type of diabetic retinopathy which is worsening by the abnormal growth of blood vessels in the back of the eye, damaging the retina.
- Trial name
- NCT00606138
- Testing
- ranibizumab, Laser photocoagulation
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Rush University Medical Center
Proliferative Diabetic Retinopathy
Prompt Panretinal Photocoagulation Versus Ranibizumab+Deferred Panretinal Photocoagulation for Proliferative Diabetic Retinopathy
The primary objective of the protocol is to determine if visual acuity outcomes at 2 years in eyes with proliferative diabetic retinopathy (PDR) that receive anti-vascular endothelial growth factor (anti-VEGF) therapy with…
- Trial name
- Protocol S (NCT01489189)
- Testing
- Prompt Panretinal Photocoagulation, 0.5-mg Ranibizumab, Deferred panretinal photocoagulation
- Where
- 48 sites in United States
- Volunteers
- 305 people
- Sponsor
- Jaeb Center for Health Research
Diabetic Retinopathy, Diabetic Macular Edema
Study of the Safety and Efficacy of APX3330 in Diabetic Retinopathy
The objective of this study is to evaluate the safety and efficacy of APX3330 to treat diabetic retinopathy (DR) and diabetic macular edema (DME).
- Conditions
- Diabetic Retinopathy, Diabetic Macular Edema, NPDR - Non Proliferative Diabetic Retinopathy, PDR - Proliferative Diabetic Retinopathy
- Trial name
- ZETA-1 (NCT04692688)
- Testing
- APX3330
- Where
- 24 sites in United States
- Volunteers
- 103 people, healthy volunteers welcome
- Sponsor
- Opus Genetics, Inc
Retinal Detachment, Diabetic Retinopathy
Avastin for PDR (Proliferative Diabetic Retinopathy)
The purpose of this study is to determine the effect of anti-VEGF drug (Avastin) adminstration in eyes prior to surgical treatment for Traction retinal detachment (TRD) in patients with Proliferative Diabetic Retinopathy (PDR).
- Trial name
- PDR (NCT01270542)
- Testing
- Avastin (bevacizumab)
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of Southern California
Proliferative Diabetic Retinopathy, Diabetic Macular Edema
Laser-Ranibizumab-Triamcinolone for Proliferative Diabetic Retinopathy
The purpose of the study is to find out if treatment with an intravitreal injection of triamcinolone or an intravitreal injection of ranibizumab can prevent loss of vision caused by panretinal photocoagulation treatment.
- Trial name
- LRTforDME+PRP (NCT00445003)
- Testing
- Ranibizumab, Triamcinolone Acetonide, Focal/grid laser
- Where
- 56 sites in United States
- Volunteers
- 333 people
- Sponsor
- Jaeb Center for Health Research
Non-Proliferative Diabetic Retinopathy, Cataract
Nepafenac Once Daily for Macular Edema - Study 1
The purpose of this study is to demonstrate superiority of Nepafenac Ophthalmic Suspension, 0.3% dosed once daily relative to Nepafenac Vehicle based upon clinical outcomes among diabetic subjects following cataract surgery.
- Trial name
- NCT01853072
- Testing
- Nepafenac Ophthalmic Suspension, 0.3%, Nepafenac vehicle, Prednisolone acetate
- Volunteers
- 881 people
- Sponsor
- Alcon Research
Diabetic Retinopathy, Posterior Vitreous Detachment
A Study to Evaluate the Efficacy and Safety of Ocriplasmin in Inducing Total PVD in Subjects With NPDR
The purpose of this study is to assess the efficacy and safety of up to 3 intravitreal injections of ocriplasmin (0.0625mg or 0.125mg), in subjects with moderate to very severe non-proliferative diabetic retinopathy (NPDR), to…
- Conditions
- Diabetic Retinopathy, Posterior Vitreous Detachment, Disease Progression
- Trial name
- CIRCLE (NCT02681809)
- Testing
- ocriplasmin 0.0625mg, ocriplasmin 0.125mg
- Where
- 38 sites in United States, Czechia and 7 more
- Volunteers
- 48 people
- Sponsor
- ThromboGenics
Vitreous Hemorrhage
Aflibercept Injection for Proliferative Diabetic Retinopathy
To evaluate the ocular and systemic safety of intravitreal aflibercept injection in patients undergoing Pars Plana Vitrectomy for Proliferative Diabetic Retinopathy.
- Trial name
- NCT01805297
- Testing
- Intravitreal Aflibercept Injection, Standard Vitrectomy
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- University of Oklahoma
Diabetic Macular Edema, Non-proliferative Diabetic Retinopathy
Ozurdex for Treatment of Recalcitrant Diabetic Macular Edema
The purpose of this study is to test the efficacy of an 0.7 mg intravitreal dexamethasone implant (Ozurdex®) on macular leakage and visual acuity for patients with recalcitrant diabetic macular edema.
- Conditions
- Diabetic Macular Edema, Non-proliferative Diabetic Retinopathy, Proliferative Diabetic Retinopathy
- Trial name
- NCT01571232
- Testing
- dexamethasone intravitreal implant, intravitreal bevacizumab
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Retina Macula Institute
Proliferative Diabetic Retinopathy, Tractional Retinal Detachment
Conbercept Injection in Treatment of Severe Proliferative Diabetic Retinopathy
To evaluate efficacy of different intravitreal Conbercept injection therapy in the treatment of severe proliferative diabetic retinopathy.
- Trial name
- NCT02816710
- Testing
- Conbercept
- Where
- China
- Volunteers
- 112 people
- Sponsor
- Ruijin Hospital
Proliferative Diabetic Retinopathy, Macular Edema
Intravitreal Ranibizumab to Treat Macular Edema After Panretinal Photocoagulation (Phase II)
This is a randomized, open-label Phase II study evaluating the safety and efficacy of intravitreally administered ranibizumab 0.5mg in subjects with Proliferative Diabetic Retinopathy experiencing post- Panretinal…
- Trial name
- NCT00668785
- Testing
- ranibizumab
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Jumper, J. Michael, M.D.
Proliferative Diabetic Retinopathy (PDR)
Multicenter 12 Months Clinical Study to Evaluate Efficacy and Safety of Ranibizumab Alone or in Combination With Laser Photocoagulation vs. Laser Photocoagulation Alone in Proliferative Diabetic Retinopathy (PRIDE)
The purpose of this study was to assess the efficacy and safety of the anti-Vascular Endothelial Growth Factor (VEGF) agent ranibizumab (0.5 mg) with or without Panretinal laser photocoagulation (PRP) compared to PRP alone in…
- Trial name
- PRIDE (NCT01594281)
- Testing
- Ranibizumab 0.5 mg, Panretinal laser photocoagulation
- Where
- 23 sites in Germany
- Volunteers
- 107 people
- Sponsor
- Novartis Pharmaceuticals
Vitreous Hemorrhage, Proliferative Diabetic Retinopathy
Intravitreal Ranibizumab for Vitreous Hemorrhage Due to Proliferative Diabetic Retinopathy (N)
This study is being conducted to determine if intravitreal injections of ranibizumab decrease the proportion of eyes in which vitrectomy is performed compared with saline injections in eyes presenting with vitreous hemorrhage…
- Trial name
- N (NCT00996437)
- Testing
- Ranibizumab, Saline
- Where
- 67 sites in United States
- Volunteers
- 261 people
- Sponsor
- Jaeb Center for Health Research
Proliferative Diabetic Retinopathy, Vitreous Hemorrhage
Anti-VEGF vs. Prompt Vitrectomy for VH From PDR
Although vitreous hemorrhage (VH) from proliferative diabetic retinopathy (PDR) can cause acute and dramatic vision loss for patients with diabetes, there is no current, evidence-based clinical guidance as to what treatment…
- Trial name
- AB (NCT02858076)
- Testing
- 2-mg Intravitreous Aflibercept Injection, Prompt Vitrectomy Plus Panretinal Photocoagulation
- Where
- 62 sites in United States, Canada
- Volunteers
- 205 people
- Sponsor
- Jaeb Center for Health Research
Visual Impairment Due to Diabetic Macular Edema
Safety and Efficacy of Ranibizumab in Diabetic Macular Edema
This study was designed to confirm the efficacy and safety of laser photocoagulation as adjunctive therapy to ranibizumab 0.5 mg versus laser monotherapy in patients with visual impairment due to Diabetic Macular Edema.
- Trial name
- RELATION (NCT01131585)
- Testing
- Active laser photocoagulation, Ranibizumab 0.5 mg
- Where
- 34 sites in Germany
- Volunteers
- 128 people
- Sponsor
- Novartis Pharmaceuticals